$0.65 0.0 0.0%
Last Trade - 20/04/21
| Market Cap | £40.7m |
| Enterprise Value | £38.6m |
| Revenue | £6.23m |
| Position in Universe | 5543rd / 6852 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Jul | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.73 | 1.29 | 1.83 | 1.77 | 1.91 | 6.92 | +56.8% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
PURE Bioscience, Inc. is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company's technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC). It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains and food processors. It is testing and continuing development of PURE Control to utilize PURE Control as a direct food contact processing aid for raw meats, including beef and pork. In addition to PURE Hard Surface and PURE Control, it manufactures and sells SDC-based products for end use; products preserved with SDC, and SDC as a raw material ingredient for manufacturing use. These products include PURE Multi-Purpose and Floor Cleaner Concentrate, PURE Multi-Purpose Hi-Foam Cleaner Concentrate, Axen 30, Axenohl and SILVERION.
| Last Annual | July 31st, 2020 |
| Last Interim | January 31st, 2021 |
| Incorporated | February 28, 2011 |
| Public Since | May 3, 2004 |
| No. of Shareholders: | n/a |
| No. of Employees: | 10 |
| Sector | Consumer Defensives |
| Industry | Personal & Household Products & Services |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 87,223,141 |
| Free Float | (0.0%) |
| Eligible for |
×
ISAs
✓
SIPPs
|
| Address | 9669 Hermosa Avenue, RANCHO CUCAMONGA, 91730, United States |
| Web | https://www.purebio.com/ |
| Phone | +1 619 5968600 |
| Contact | Mark Elliott (Principal Financial Officer, Principal Accounting Officer, Vice President - Finance) |
| Auditors | Mayer Hoffman & McCann P.C. |
As of 20/04/21, shares in PURE Biosciences Inc are trading at $0.65, giving the company a market capitalisation of £40.7m. This share price information is delayed by 15 minutes.
Shares in PURE Biosciences Inc are currently trading at $0.65 and the price has moved by 4.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the PURE Biosciences Inc price has moved by -30.56% over the past year.
Of the analysts with advisory recommendations for PURE Biosciences Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for PURE Biosciences Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.
PURE Biosciences Inc is scheduled to issue upcoming financial results on the following dates:
PURE Biosciences Inc does not currently pay a dividend.
PURE Biosciences Inc does not currently pay a dividend.
PURE Biosciences Inc does not currently pay a dividend.
To buy shares in PURE Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in PURE Biosciences Inc are currently trading at $0.65, giving the company a market capitalisation of £40.7m.
Here are the trading details for PURE Biosciences Inc:
Based on an overall assessment of its quality, value and momentum, PURE Biosciences Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for PURE Biosciences Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PURE Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been -63.11%. At the current price of $0.65, shares in PURE Biosciences Inc are trading at -41.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The PURE Biosciences Inc PE ratio based on its reported earnings over the past 12 months is 62.98. The shares are currently trading at $0.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
PURE Biosciences Inc's management team is headed by:
Here are the top five shareholders of PURE Biosciences Inc based on the size of their shareholding:
